TCM
AMLX icon

TCG Crossover Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

TCG Crossover Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112M Hold
6,243,812
– – 2.7% 10
2026
Q1 		$86.8M Hold
6,243,812
– – 2.48% 13
2025
Q4 		$75.4M Hold
6,243,812
– – 2.5% 9
2025
Q3 		$84.9M Buy
6,243,812
+300,000
+5% +$2.82M 4.17% 4
2025
Q2 		$38.1M Hold
5,943,812
– – 4.35% 7
2025
Q1 		$21M Buy
5,943,812
+1,300,000
+28% +$4.63M 2.87% 15
2024
Q4 		$17.6M Hold
4,643,812
– – 1.72% 25
2024
Q3 		$15M Buy
+4,643,812
New +$10.4M 1.27% 24

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

TCG Crossover Management's AMLX Position: Q2 2026 in Review

TCG Crossover Management held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 6,243,812 shares worth $112M. The position accounts for 2.7% of the portfolio, ranked #10.

TCG Crossover Management first reported a position in AMLX in Q3 2024 and has held it in 8 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • TCG Crossover Management held 6,243,812 shares of Amylyx Pharmaceuticals worth $112M as of Q2 2026.
  • TCG Crossover Management left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
  • Amylyx Pharmaceuticals made up 2.7% of TCG Crossover Management's portfolio in Q2 2026, its #10 holding.
  • TCG Crossover Management first reported a position in Amylyx Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.